{"groups":[{"description":"Cabozantinib (XL184) 60 mg tablet once daily.\n\nCabozantinib tablets","id":"FG000","title":"Cabozantinib (XL184)"},{"description":"Everolimus (Afinitor) 10 mg tablet once daily.\n\nEverolimus (Afinitor) tablets","id":"FG001","title":"Everolimus (Afinitor)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"31"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"50"}],"type":"Clinical Deterioration"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"11"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"122"},{"groupId":"FG001","numSubjects":"158"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Reason Not Provided"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"330"},{"groupId":"FG001","numSubjects":"328"}],"comment":"Randomized","type":"STARTED"},{"achievements":[{"comment":"One subject randomized to everolimus arm received cabozantinib discontd due to clin. deterioration","groupId":"FG000","numSubjects":"132"},{"comment":"Five subjects were randomized but not treated","groupId":"FG001","numSubjects":"73"}],"comment":"Continuing study treatment at the time of data cut-off","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"198"},{"groupId":"FG001","numSubjects":"255"}],"type":"NOT COMPLETED"}],"title":"Overall Study (ITT)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"20"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"29"}],"type":"Clinical Deterioration"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"92"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"187"},{"comment":"Three subjects in the everolimus arm were randomized but not treated.","groupId":"FG001","numSubjects":"188"}],"comment":"PITT population consisted of the first 375 subjects randomized to received study treatment.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"36"}],"comment":"Continuing study treatment at the time of data cut-off","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"131"},{"groupId":"FG001","numSubjects":"152"}],"type":"NOT COMPLETED"}],"title":"Primary Intent to Treat (PITT)"}],"recruitmentDetails":"First patient enrolled: 08 August 2013, Data cut off date: 22 May 2015"}